Literature DB >> 12403056

Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man.

Virpi Saareks1, Pauli Ylitalo, István Mucha, Asko Riutta.   

Abstract

The effects of nicotinic acid (2500 mg orally during 12 hr) and pyridoxine (300 mg orally twice daily for seven days) on the excretion of urinary 2,3-dinor-6-ketoprostaglandin F1alpha, 11-dehydrothromboxane B2 and leukotriene E4, the markers of systemic prostacyclin, thromboxane A2 and cysteinyl leukotriene production, respectively, were investigated in healthy male volunteers (n=6-8). Nicotinic acid increased 11-dehydrothromboxane B2 and leukotriene E4 excretions to 2.6- and 2.0 times the initial values (P<0.05), respectively. In the volunteers treated with pyridoxine, 11-dehydrothromboxane B2 and leukotriene E4 excretions were decreased to 70% (P<0.05) and 65% (P<0.01) of the initial values, respectively, but the excretion of 2,3-dinor-6-ketoprostaglandin F1alpha was increased 1.7 times (P<0.01). The results suggest that nicotinic acid increases thromboxane and leukotriene synthesis which may not be beneficial for patients with cardiovascular diseases or asthma. In contrast, the increase in prostacyclin production and the inhibition in thromboxane and leukotriene synthesis by pyridoxine might be beneficial in disorders where the production of prostacyclin is decreased and the formation of thromboxane and cysteinyl leukotrienes is enhanced.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12403056     DOI: 10.1034/j.1600-0773.2002.900608.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  3 in total

1.  Pharmacogenomics: novel loci identification via integrating gene differential analysis and eQTL analysis.

Authors:  Weiliang Qiu; Angela J Rogers; Amy Damask; Benjamin A Raby; Barbara J Klanderman; Qing Ling Duan; Shiva Tyagi; Simin Niu; Christopher Anderson; Ellen Cahir-Mcfarland; Thomas J Mariani; Vincent Carey; Kelan G Tantisira
Journal:  Hum Mol Genet       Date:  2014-04-25       Impact factor: 6.150

2.  Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

Authors:  Kang Cheng; Tsuei-Ju Wu; Kenneth K Wu; Claudio Sturino; Kathleen Metters; Keith Gottesdiener; Samuel D Wright; Zhaoyin Wang; Gary O'Neill; Eseng Lai; M Gerard Waters
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

3.  Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation.

Authors:  Sonia Philipose; Viktoria Konya; Mirjana Lazarevic; Lisa M Pasterk; Gunther Marsche; Sasa Frank; Bernhard A Peskar; Akos Heinemann; Rufina Schuligoi
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.